PLEASANTON,Calif.,Sept. 13,2024 -- NiceTop™️,a U.S.-based anti-aging research team,has launched a new hair growth supplement,marking its latest foray into the personal care and nutrition market.
The NiceTop™️brand team,founded in 2012,announced the release of NiceTop™️Hair Grow,a nutritional supplement designed to address multiple facets of hair loss and regrowth.
"Our new formula targets three key aspects of hair health: inhibiting DHT-induced hair loss,providing essential nutrients for hair growth,and accelerating the process with biotin," said a NiceTop™️spokesperson,who requested anonymity due to company policy.
The Hair Grow supplement combines saw palmetto extract,marine pine bark extract,keratin,vitamins C and E,folic acid,minerals,and biotin. NiceTop™️claims this comprehensive approach sets it apart from competitors that typically focus on either nutrition or biotin supplementation alone.
This launch is part of a broader product expansion by NiceTop™️,which has historically focused on anti-aging solutions for women across cosmetics,beauty devices,and nutritional supplements.
Other recent additions to their product line include:
Brain Power: A supplement aimed at improving learning efficiency in school-aged adolescents,combining Korean red ginseng withphosphatidylserine.
Metabolic Activator: A weight management product incorporating traditional Eastern herbs like mulberry leaf and bitter melon withPQQ (pyrroloquinoline quinone) to enhance metabolic function.
NiceTop™️,which operates in the United States,European Union,and Asian markets,stated it plans to continue research in probiotics and natural products for future supplement developments.
The global hair care market,including supplements,is projected to reach $211.1 billion by 2025,according to Grand View Research,with increasing concerns over hair loss driving growth in the supplement segment.
NiceTop™️has not disclosed specific sales targets for the new product line. The effectiveness and safety of dietary supplements are not typically evaluated by the U.S. Food and Drug Administration.
12-23
12-20
12-20
12-20
12-20
12-20
12-20
12-20
12-20
12-20